Kagawa Tatehiro
- 教授
- 学位：博士（医学）
基本情報
所属
- Undergraduate School of Medicine / Faculty of Medicine
- Graduate School of Medicine / Course of Advanced Medical Science
- Graduate School of Medicine / Course of Medical Science
ジャンル
- Cancer Treatment
- Drugs
- Lifestyle-Related Diseases
- Infectious Disease
研究と関連するSDGs
詳細情報
研究キーワード
- hepatocellular carcinoma
- liver cirrhosis
- hepatitis
- cholestasis
- Bile secretion
研究分野
- Life sciences Gastroenterology hepatology
受賞
- Hepatology Research Award
- The Japanese Society of Gastroenterology Young Investigator Award
論文
Metabolic Vulnerability and Tamoxifen Hepatotoxicity: The Importance of Multidisciplinary Collaboration
Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma
Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial.
Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan
Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug-Induced Liver Injury.
Liver-specific Nr1h4 deletion in mice with human-like bile acid composition causes severe liver injury.
Arrhythmias in Cronkhite-Canada Syndrome.
Current Status of Hepatitis Medical Care Coordinators in Regional Core Centers for Liver Disease Management in Japan: Results of the Third Survey
A Pilot Study Using a Smartwatch to Search for Biomarkers of Heart Rate Variability in Active Ulcerative Colitis.
Difficulty Confirming the Diagnosis of Amoebic Enteritis.
Immune-related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan.
Impact of Atezolizumab + Bevacizumab Therapy on Health-Related Quality of Life in Patients with Advanced Hepatocellular Carcinoma.
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
書籍等出版物
- Weekly administration of interferon in the treatment for chronic viral hepatitis
講演・口頭発表等
- Clinical significance of circulating biomarkers of immune-checkpoint molecules wit atezolizumab plus bevacizumab therapy in unresectable HCC
- Generation of Liver-Specific FXR-Deficient Mice with a Human-Like Bile Acid Profile and Development of Novel Therapeutic Approaches
- The effect of corticosteroid use on prognosis during atezolizumab + bevacizumab combination therapy
- Development of PFIC Mouse Models with Human-Like Bile Acid Composition via Liver-Specific CRISPR/Cas9-Mediated Gene Deletion
- Analyses of pluripotent stem cell-derived liver culture system regulated by transcription factors
- A Study Protocol to Evaluate the Effectiveness of Cognitive Behavioral Therapy in Optimizing Lifestyle Behaviors in Patients with MASLD
- Reduced health-related quality of life predicts poor outcomes in advanced hepatocellular carcinoma patients treated with atezolizumab and bevacizumab
- Pemafibrate improves liver function with alteration of bile acid composition and gut microbiota in patients with steatotic liver disease
所属学会
- American Physiological Society
- American Association for the Study of Liver Diseases
共同研究・競争的資金等の研究課題
Treatment for hepatocellular carcinoma
Study on viral hepatitis
bile salt exprot pump
Study on the mechanism in biliary secretion
ResearchMapへ移動します
Contact Us
Inquiries about coverage
Public Affairs Division Public Affairs and Communications Department
Tel. 0463-63-4670（direct dialing）